产能扩充 2026年1月31日及2月3日，公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为-4.8亿元 至-3.6亿元，主要因对子公司安徽恒星制药和广西裕源药业计提商誉减值4.4亿元至5.4亿元所致。若剔 除该减值影响，主业归母净利润为6000万元至8000万元，显示核心业务企稳。此次减值为非经常性损 益，公司称旨在优化资产结构、缓释风险。 公司状况 商誉减值源于2021年并购安徽恒星制药的业绩承诺未达预期，目前公司与原股权转让方就2.56亿元尾款 支付存在诉讼纠纷，进展存在不确定性。公司计划对涉事子公司推进产能提升、渠道拓展及产品结构优 化，以逐步改善盈利能力。 经济观察网华仁药业（300110）2025年业绩预亏，主要因对两家子公司计提大额商誉减值；同时，公司 肾科业务产能扩张，并出现高管变动。 业绩经营情况 2025年11月，日照工厂腹膜透析液第一条生产线投产，年产能提升至5100万袋；第二条生产线已建成并 进入调试阶段，全部投产后总产能将达6200万袋，进一步巩固市场供应能力。公司肾科业务作为战略核 心，腹膜透析液销量与收入在2025年保持增长。 高管变动 2025年12月，持股5%以上 ...

格隆汇2月4日丨华仁药业(300110.SZ)在互动平台表示，公司目前暂无相关检测产品。 ...

证券代码：300110 证券简称：华仁药业 公告编号：2026-002 华仁药业股份有限公司 2025 年度业绩预告 | 项目 | | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | | -48,000 | ～ | -36,000 | -136,847.90 | | | 比上年同期增长 | 64.92% | ～ | 73.69% | | | 扣除非经常性损 | | -49,000 | ～ | -37,000 | -137,819.20 | | 益后的净利润 | 比上年同期增长 | 64.45% | ～ | 73.15% | | 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师审计。公司已就业绩预告有关事项与为公司 提供年度审计服务的会计师事务所进行了预沟通，双方在本次业绩预告方面不 存在分歧。 三、业绩变动原因说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 ...

（编辑 任世碧） 证券日报网讯 1月23日，华仁药业在互动平台回答投资者提问时表示，二级市场股价波动受多方面因素 影响。公司管理层始终以公司长远发展和股东利益为重，未来将继续努力提升公司经营质量，加速实施 提升盈利能力的各项举措，努力提升上市公司投资价值，增强投资者回报水平。 ...

Core Viewpoint - The company is actively expanding its product lines in the health sector, including beverages, cosmetics, and health drinks, with a focus on brand and channel development for future growth [1] Group 1: Beverage Business - The beverage segment includes products such as electrolyte supplements, purified water, large bottled water, glucose rehydration solutions, and solid beverages [1] Group 2: Cosmetics Business - The cosmetics division features products developed through a collaboration between the subsidiary Hubei Huaren Tongji and Tongji Hospital, focusing on medical science skincare [1] - Key products include collagen sleep masks, small molecule collagen water, vitamin E moisturizing cream, aurora night essence, vitamin E lotion, and sunscreen [1] Group 3: Health Drinks - The health drink line includes the "Huaren Tongji Bird's Nest Collagen Tripeptide Drink," which has been launched and is supported by the "Huaren Tongji Joint Laboratory" [1] - Currently, the sales revenue from this product line is relatively small, but the company plans to enhance brand and channel development for both online and offline sales [1]

Group 1 - The company emphasizes that its stock price is influenced by multiple factors and it takes stock performance seriously [1] - The company is driving rapid and stable development of its main business through internal growth and external mergers and acquisitions [1] - The company's operating conditions for 2025 will be disclosed in the annual report for that year [1]

Group 1 - The company, Huaren Pharmaceutical, stated that it will disclose shareholder information in its annual report for the year ending December 31, 2025 [1] - Investors are advised to pay attention to announcements on official platforms such as the Giant Tide Information Network [1]

证券日报网讯1月7日，华仁药业（300110）在互动平台回答投资者提问时表示，公司将基于最大化挽回 损失的原则，持续积极跟进债务化解进度，最大程度维护公司及全体股东的合法权益。 ...

证券代码：300110 证券简称：华仁药业 公告编号：2026-001 重要内容提示： 1、案件所处诉讼阶段：一审裁定； 2、公司及子公司所处的当事人地位：公司及全资子公司西安曲江华仁药业有 限公司为被告，公司全资子公司安徽恒星制药有限公司为第三人； 3、涉案金额：人民币 284,288,000 元； 4、对上市公司损益产生的影响：本公告所述的诉讼案件民事裁定结果可以在 规定期限内提起上诉，案件最终结果尚存在不确定性，目前暂无法判断对公司本期 或期后利润的影响。 华仁药业股份有限公司（以下简称"华仁药业"或"公司"）及全资子公司西安曲 江华仁药业有限公司（以下简称"曲江华仁"）、全资子公司安徽恒星制药有限公司 （以下简称"安徽恒星"）于近日收到西安市中级人民法院作出的《民事裁定书》（案 号：（2024）陕 01 民初 302 号之二），现将涉及的诉讼进展情况公告如下： 一、本次诉讼的基本情况 华仁药业股份有限公司 关于重大诉讼的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 三、其他尚未披露的诉讼仲裁事项 因股权转让纠纷，宜春聚特星商贸中心（有限合伙 ...

Summary of Key Points Core Viewpoint - Huarun Pharmaceutical's stock closed at 3.15 yuan on December 31, with a slight increase of 0.32%. The stock experienced three block trades totaling 1.2967 million shares and a transaction value of 3.6826 million yuan, indicating active trading interest despite recent declines [1]. Trading Activity - The first block trade occurred at a price of 2.84 yuan for 300,000 shares, amounting to 852,000 yuan, with a discount rate of -9.84%. The buyer was an institutional investor, and the seller was China Galaxy Securities Co., Ltd. [1] - The second block trade also took place at 2.84 yuan, involving 529,200 shares and a total value of 1.5029 million yuan, maintaining the same discount rate of -9.84%, with the buyer being an institutional investor and the seller being Guosheng Securities Co., Ltd. [1] - The third block trade matched the previous prices, with 467,500 shares traded at 2.84 yuan, resulting in a transaction value of 1.3277 million yuan and a discount rate of -9.84%, with the buyer again being an institutional investor and the seller being China Galaxy Securities Co., Ltd. [1] Recent Performance - Over the past three months, Huarun Pharmaceutical has recorded a total of 19 block trades, with a cumulative transaction value of 36.5743 million yuan. In the last five trading days, the stock has seen a decline of 1.87%, with a net outflow of 1.336 million yuan in principal funds [1].